Valneva

Valneva Gross Margin

The Gross Margin of Valneva (VLA.PA) as of Oct 18, 2026 is 38.66 %. In the previous year, Gross Margin was 41.89 % — a change of -7.72% (lower).

Gross Margin

38.66 %

YoY

-7.72%

Last updated:

Gross Margin of Valneva is 2025 38.66 % . Gross Margin of Valneva was 2024 41.89 % . It decreases by -7.72% lower compared to the previous year.

For Valneva, the gross margin of 38.7% is down versus 46.0% a few years ago.

The Valneva Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
61.58 EUR
Jan 1, 2019
60.40 EUR
Jan 1, 2020
50.78 EUR
Jan 1, 2021
46.01 EUR
Jan 1, 2022
10.20 EUR
Jan 1, 2023
34.37 EUR
Jan 1, 2024
41.89 EUR
Jan 1, 2025
38.66 EUR
The Valneva Gross Margin history
YEARGross MarginYoY
38.66 %-7.72%
41.89 %+21.87%
34.37 %+236.92%
10.20 %-77.83%
46.01 %-9.38%
50.78 %-15.94%
60.40 %-1.90%
61.58 %+9.31%
56.33 %+3.92%
54.20 %+35.28%
40.07 %-25.20%
53.57 %+11,601.84%
0.46 %-120.49%
-2.23 %-747.42%
0.35 %+56.06%
0.22 %-131.67%
-0.70 %-454.50%
0.20 %-120.87%
-0.94 %-237.07%
0.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

Gross Margin of Valneva is 38.66 % in 2025.

Gross Margin of Valneva changed from 41.89 % to 38.66 %, representing a -7.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Valneva since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Valneva with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Valneva

All Key Metrics — Valneva